Novartis AG (SWX:NOVN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 208.23B |
| Revenue (ttm) | 44.95B |
| Net Income (ttm) | 11.48B |
| Shares Out | 1.92B |
| EPS (ttm) | 5.82 |
| PE Ratio | 18.65 |
| Forward PE | 15.63 |
| Dividend | 3.50 (3.23%) |
| Ex-Dividend Date | Mar 11, 2025 |
| Volume | 8,192,305 |
| Average Volume | 3,223,708 |
| Open | 108.32 |
| Previous Close | 107.74 |
| Day's Range | 107.14 - 108.58 |
| 52-Week Range | 81.10 - 109.16 |
| Beta | 0.44 |
| RSI | 63.85 |
| Earnings Date | Feb 4, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial numbers in USD Financial StatementsNews
Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal
President Donald Trump and nine major pharmaceutical companies announced agreements to lower the cost of medications for cash payers and the government’s Medicaid program on Friday, bringing U.S. cost...
Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay
The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.
Novartis (NVS) Gains FDA Orphan Drug Status for Iptacopan
Novartis (NVS) Gains FDA Orphan Drug Status for Iptacopan
Novartis (NVS) Reaches Agreement with U.S. to Lower Drug Prices and Boost Investment
Novartis (NVS) Reaches Agreement with U.S. to Lower Drug Prices and Boost Investment
Trump strikes deal with US drugmakers to cut Medicaid medicine costs
Officials pledge ‘massive savings’ as companies agree to offer drugs at prices equal to those in other wealthy nations Donald Trump and nine major pharmaceutical companies on Friday announced deals th...
Nine of the largest pharma companies ink deals with Trump to lower drug prices
Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation's drug...
Novartis and US government reach agreement on lowering drug prices in the US
Basel, December 19, 2025 – Novartis, a leading global innovative medicines company, today announced it has reached an agreement with the US government that aims to lower the price of innovative medici...
Novartis (NVS) Gains FDA Orphan Status for Myasthenia Gravis Treatment
Novartis (NVS) Gains FDA Orphan Status for Myasthenia Gravis Treatment
White House Readies Drug Price Deals With AbbVie, Novartis, Roche
AbbVie Inc. (NYSE: ABBV) and several other drugmakers are reportedly expected to announce agreements with the U.S. government on Friday to cut select prescription drug prices and comply with addition...
Novartis, Roche back US efforts to lower drug costs amid talk of pricing deal
Swiss pharma giants Novartis and Roche on Thursday backed U.S. efforts to lower the cost of drugs and are working with the Trump administration towards that goal following a report they are close to a...
AbbVie, several other pharma companies near MFN deal with Trump, sources say
AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain prescription drug prices and meet other demands made by President Donald Tru...
White House to Reveal Drug Pricing Agreements with Novartis (NVS)
White House to Reveal Drug Pricing Agreements with Novartis (NVS)
Novartis, Roche near US drug price deal, Bloomberg News reports
The White House is set to announce drug pricing deals with pharmaceutical heavyweights Novartis AG and Roche Holding AG as soon as Friday, Bloomberg News reported on Wednesday citing people familiar w...
Salesforce (CRM) Chosen by Novartis to Enhance Patient Engagement
Salesforce (CRM) Chosen by Novartis to Enhance Patient Engagement
Salesforce's Agentforce Life Sciences Selected by Novartis to Drive More Personalized Customer Engagement Globally
SAN FRANCISCO--(BUSINESS WIRE)--Salesforce (NYSE: CRM), the world's #1 AI CRM, announced today that Novartis (NYSE: NVS), a leading global innovative medicines company, has selected Salesforce's Agent...
The Zacks Analyst Blog Microsoft, Novartis, RTX and Air T
Microsoft leads Zacks??? top research picks today, alongside Novartis and RTX, highlighting cloud, pharma innovation and defense demand shaping 2025.
Top Research Reports for Microsoft, Novartis & RTX
Microsoft, Novartis and RTX headline Zacks' top research picks, spotlighting cloud, pharma innovation and defense demand shaping market leaders.
Notable healthcare headlines for the week: CVS, Eli Lilly and Novartis in focus
Novartis (NVS) Expands Manufacturing Presence in North Carolina
Novartis (NVS) Expands Manufacturing Presence in North Carolina
Novartis Breaks Ground In North Carolina For New Manufacturing Hub, To Create 700 New Jobs
(RTTNews) - Novartis AG (NVS), the Swiss pharmaceutical major, Friday announced that it broke ground yesterday on more than 700,000-square-foot flagship manufacturing hub in North Carolina.
Novartis breaks ground on flagship manufacturing hub in North Carolina
East Hanover, December 12, 2025 – Novartis, a leading global innovative medicines company, broke ground yesterday on its more than 700,000-square-foot flagship manufacturing hub in North Carolina, mov...
Novartis' Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder
Novartis AG (NYSE: NVS) on Tuesday shared results from the VAYHIT2 Phase 3 trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously treated with corticost...
Novartis' Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder
Novartis AG (NYSE: NVS) on Tuesday shared results from the VAYHIT2 Phase 3 trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously treated with corticoste...
Novartis sees positive results when ianalumab added to Promacta for thrombocytopenia
Novartis (NVS) Reveals Promising Kisqali Results for Advanced Breast Cancer
Novartis (NVS) Reveals Promising Kisqali Results for Advanced Breast Cancer